(Q42032199)

English

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

scientific article published on 20 May 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

2

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Jorge Eduardo Cortes

8

object named as

Jorge Cortes

1 reference

Europe PubMed Central

15 October 2017

PMC publication ID

5

object named as

Susan O'Brien

1 reference

Europe PubMed Central

15 October 2017

PMC publication ID

6

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Gautam Borthakur

4

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

15 October 2017

PMC publication ID

Guillermo Garcia-Manero

3

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

15 October 2017

PMC publication ID

Constantine S. Tam

1

object named as

Constantine S Tam

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Jenny Pui Shan Wong

7

object named as

Jenny Shan

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

language of work or name

0 references

publication date

20 May 2008

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

112

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

516-518

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

5 June 2018

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

5 June 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

5 June 2018

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

5 June 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

5 June 2018

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

17 August 2018

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

17 August 2018

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4082324

2 December 2018

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/18492956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18492956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-02-141580

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42032199&oldid=1932303939"